Sirona Biochem to Present Scientific Poster at Canadian Diabetes Professional Conference

Vancouver, British Columbia, CANADA

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 4, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce it has been selected to present a scientific poster at the annual Canadian Diabetes Association Professional Conference to be held October 11-13, 2012 in Vancouver, B.C.

"Recent results of SGLT Inhibitors such as canagliflozin and dapagliflozin show this is an innovative new class of potential treatments for diabetes," said Dr. Bertrand Plouvier, Vice President of Product Development at Sirona Biochem. "We are excited to further demonstrate the efficacy of this potential new class of diabetes treatments and share our positive preclinical results of our SGLT Inhibitor, SBM-TFC-039," he added.

Sirona Biochem's scientific poster titled "In Vivo Efficacy of Novel Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor SBM-TFC-039 on Glucose Excretion and Tolerance in Normal Sprague-Dawley and Zucker Diabetic Fatty Rats" will be displayed in the Exhibit Hall throughout the duration of the conference. Sirona Biochem's Vice President of Product Development, Dr. Bertrand Plouvier, will be in attendance and will present the poster.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Sirona Biochem Corp.
Julie Jang
Director, Communications